# GLP-1

Type: Technology

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/glp-1
Canonical HTML page: https://getlegalbrief.com/entity/glp-1

## Timeline

- **2026-07-21**: Lawsuit filed — Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising.
- **2026-04**: Cease-and-desist letter — Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.
- **2026-03**: Settlement Reached — Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
- **2026-03**: High-dose Wegovy approved — Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.
- **2025**: Litigation Surge — Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
- **2024**: FDA Shortage Updates — FDA begins removing specific GLP-1 dosages from the national shortage list.
- **2024-05**: HIMS Launches GLP-1s — Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.

## Recent coverage (2 stories)

### Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims
2026-07-21 22:05:06 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-misleading-glp1-ads-lanham-act

### Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement
2026-03-09 17:30:26 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Full story: https://getlegalbrief.com/story/hims-hers-glp1-settlement-regulation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.